ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,459.10
      1.11%
      US Tech 100
      18,514.00
      1.00%
      Dow Jones
      40,589.34
      1.64%
      Brent Oil
      79.745
      0.00%
      Bitcoin
      67,846.96
      -0.10%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Lexicon Pharmaceuticals Inc (LXRX) Quote

      Lexicon Pharmaceuticals Inc

      Lexicon Pharmaceuticals Inc (LXRX)

      NASDAQ
      2.39
      0.06
      (2.58%)
      Closed July 27 4:00PM
      Delayed by 15 minutes
      2.40
      0.01
      (0.42%)
      After Hours: 6:18PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      2.40
      Bid
      1.55
      Ask
      2.50
      Volume
      3,136,794
      2.32 Day's Range 2.44
      0.92 52 Week Range 3.73
      Market Cap
      590.968M
      Previous Close
      2.33
      Open
      2.43
      Last Trade
      1
      @
      2.4
      Last Trade Time
      Financial Volume
      $ 7,482,096
      VWAP
      2.3853
      Average Volume (3m)
      2,639,493
      Shares Outstanding
      246,236,753
      Dividend Yield
      -
      PE Ratio
      -3.31
      Earnings Per Share (EPS)
      -0.72
      Revenue
      1.2M
      Net Profit
      -177.12M

      About Lexicon Pharmaceuticals Inc

      Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for ... Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.lexpharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Lexicon Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LXRX. The last closing price for Lexicon Pharmaceuticals was $2.33. Over the last year, Lexicon Pharmaceuticals shares have traded in a share price range of $ 0.92 to $ 3.73.

      Lexicon Pharmaceuticals currently has 246,236,753 shares outstanding. The market capitalization of Lexicon Pharmaceuticals is $573.73 million. Lexicon Pharmaceuticals has a price to earnings ratio (PE ratio) of -3.31.

      Lexicon Pharmaceuticals (LXRX) Options Flow Summary

      LXRX Options Flow

      Overall Flow

      Bullish

      Net Premium

      200k

      Calls / Puts

      100.00%

      Buys / Sells

      100.00%

      OTM / ITM

      100.00%

      Sweeps Ratio

      0.00%

      LXRX Latest News

      More News

      Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

      THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the...

      July 25 2024
      GlobeNewswire Inc.

      Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

      Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type...

      July 16 2024
      GlobeNewswire Inc.

      New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

      New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings...

      July 15 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      July 08 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      July 08 2024
      Edgar (US Regulatory)

      Form 3 - Initial statement of beneficial ownership of securities

      July 08 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      July 08 2024
      Edgar (US Regulatory)

      Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

      THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief...

      July 08 2024
      GlobeNewswire Inc.

      Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

      Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and...

      June 21 2024
      GlobeNewswire Inc.

      Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

      Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP...

      June 19 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.33816.39185257032.0622.451.9437842362.18091211CS
      40.6436.36363636361.762.451.5631733051.97970617CS
      120.7444.5783132531.662.451.5626394931.86061579CS
      260.5630.43478260871.843.731.4836801402.20455515CS
      520.4321.82741116751.973.730.9230093391.87373721CS
      156-1-29.41176470593.46.32990.9216624752.29619863CS
      260-3.2-57.14285714295.69.650.9220373333.111874CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WINTWindtree Therapeutics Inc
      $ 8.24
      (150.46%)
      		48.57M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NBSTWNewbury Street Acquisition Corporation
      $ 0.1349
      (92.71%)
      		122.1k
      YIBOPlanet Image International Ltd
      $ 2.915
      (53.43%)
      		260.07k
      CREVCarbon Revolution Public Ltd
      $ 9.00
      (45.87%)
      		8.06M
      NMHINatures Miracle Holding Inc
      $ 0.2035
      (-48.06%)
      		7.69M
      TANHTantech Holdings Ltd
      $ 0.2585
      (-47.23%)
      		6.75M
      DXCMDexCom Inc
      $ 64.00
      (-40.66%)
      		53.92M
      PSIGPS International Group Ltd
      $ 1.42
      (-31.40%)
      		716.26k
      POAIPredictive Oncology Inc
      $ 1.36
      (-27.27%)
      		6.02M
      SLNASelina Hospitality PLC
      $ 0.0305
      (-18.88%)
      		408.61M
      BFIBurgerFi International Inc
      $ 0.4206
      (97.37%)
      		313.59M
      NVDANVIDIA Corporation
      $ 113.06
      (0.69%)
      		293.33M
      SQQQProShares UltraPro Short QQQ
      $ 9.10
      (-2.88%)
      		176.49M
      SGMOSangamo Therapeutics Inc
      $ 0.8612
      (28.15%)
      		123.71M

      LXRX Discussion

      View Posts
      Monksdream Monksdream 7 days ago
      LXRX under $2
      👍️0
      BooDog BooDog 2 weeks ago
      Just may be an early Christmas. https://www.globenewswire.com/news-release/2024/07/16/2913701/0/en/Lexicon-Pharmaceuticals-Receives-December-20-2024-PDUFA-Goal-Date-for-Sotagliflozin-Type-1-Diabetes-NDA-Resubmission.html
      👍️0
      Monksdream Monksdream 3 weeks ago
      LXRX under $2
      👍️ 1
      jdheart101 jdheart101 3 months ago
      Garbage
      👍️0
      dcaf7 dcaf7 3 months ago
      Interesting sales estimates for Sota.
      Apr 30, 2024
      Leerink initiated coverage of Lexicon with an Outperform rating and $5 price target. The firm believes Lexicon’s first-in-class dual SGLT1/2 inhibitor sotagliflozin could address unmet need across multiple indications with large market opportunities, including heart failure, hypertrophic cardiomyopathy and Type 1 diabetes with chronic kidney disease, which could collectively drive blockbuster sales. Inpefa’s U.S. launch in HF should benefit from several meaningful tailwinds, Leerink says. It forecasts peak U.S. sales of $1B for Inpefa in HF and peak U.S. sales of $325M for sotagliflozin in HCM in FY32. The firm also points out that Lexicon plans to resubmit Zynquista’s NDA filing by mid-2024, with an anticipated 6-month review. Leerink forecasts peak U.S. sales of $225M for Zynquista in T1D with CKD in FY32.
      👍️0
      BooDog BooDog 3 months ago
      Almost added back in but want to see confirmation for bottom. Double bottoms can be tricky. But even so, long term I like this.
      👍️0
      BooDog BooDog 3 months ago
      Zacks analysis.
      https://www.zacks.com/stock/news/2256264/all-you-need-to-know-about-lexicon-lxrx-rating-upgrade-to-buy

      Upgrading to buy while I'm watching for the gap to fill which may put this around 1.40's. We'll see. I think analysts are always late to the party but this report is actually pretty timely.
      👍️0
      BooDog BooDog 4 months ago
      Quite the gap there if that's what you're looking at.
      👍️0
      glenn1919 glenn1919 4 months ago
      LXRX.......................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      dcaf7 dcaf7 5 months ago
      Lexicon will resubmit an NDA for sotagliflozin for patients with type 1 diabetes and chronic kidney disease. Good news. FDA rejected an NDA for type 1 diabetes in 2019. Now they changed their mind but only for patients with T1D+CKD. According to today's company presentation, slide 10, this population makes 21% of adults with T1D, or ~357,000 patients. Not a big addition to current indication. However, it will be the first gliflozin approved for T1D. No competition.
      👍️ 1
      Awl416 Awl416 5 months ago
      Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
      👍️0
      BooDog BooDog 5 months ago
      Earnings expected next Thursday, a miss or a hit? Revenue a hit imo.

      Form 4 filed
      👍️0
      jdheart101 jdheart101 5 months ago
      200 July 2.5 calls @.88 . Be back soon !!!
      👍️0
      TIMGZ TIMGZ 6 months ago
      INBS**** AS ALWAYS SUPER FAST COMPUTERS***WHALES***HEDGES FUNDS*** TRADERS MIGHT SURGE THE VOLUME AT A VERY HIGH FREQUENCY****


      WITHIN MINUTES*****UPTREND

      SEEMS SETTING UP NICELY FOR THAT
      👍️0
      BooDog BooDog 6 months ago
      Still looking pretty good here. Did trim a few 2.38's thouigh. Not sure if we'll see a reset soon or not.

      👍️0
      glenn1919 glenn1919 6 months ago
      LXRX..........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      jdheart101 jdheart101 6 months ago
      Another 4000. @1.76
      👍️0
      Legend431 Legend431 6 months ago
      Oops
      👍️0
      jdheart101 jdheart101 6 months ago
      I’m in today 9500 @1.49 1/23/24
      👍️0
      BooDog BooDog 8 months ago
      Ready to see this rock and roll. Get the Christmas rally going!

      https://www.inpefahcp.com/


      Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. Wikipedia
      Stock price: LXRX (NASDAQ) $1.16 +0.01 (+1.32%)
      Dec 6, 10:18?AM EST - Disclaimer
      Headquarters: The Woodlands, TX
      CEO: Lonnel Coats (Jul 7, 2014–)
      Revenue: 324.1 million USD (2019)
      Number of employees: 225 (2011)
      Founded: 1995, The Woodlands, TX
      Founder: Arthur T Sands
      Subsidiaries: Lex-Gen Woodlands, L.P., Lexicon Pharmaceuticals (New Jersey), Inc
      Product
      https://www.lexpharma.com/

      https://www.lexpharma.com/media-center/news
      👍️0
      BooDog BooDog 8 months ago
      Insider buying... Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

      https://finance.yahoo.com/news/director-philippe-amouyals-strategic-200-060356510.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAIoi6pMjBlhAAWCTqsgFDgJ_L3Mq27MaOD9VoCvqo193rq8IznDFhr2okgZCfdpTcOoOQpbq-htdQ0dRd_C7SPjLqq1-XLfxoxxNvrWLXCfYfWwGJkWm40NnRnChJ7IS-3NNjcnArKcxghtaIU9gZcRtqotAVRnZUPj9phWfJymM
      👍️0
      Monksdream Monksdream 8 months ago
      LXRX new 52 week low
      👍️0
      BooDog BooDog 9 months ago
      $LXRX. Looking good. See this in a week or 2.

      JMHO.
      👍️0
      glenn1919 glenn1919 9 months ago
      LXRX................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      TRADER99 TRADER99 10 months ago
      Looks like we saw a bottom here with this spike in volume
      👍️0
      Monksdream Monksdream 10 months ago
      LXRX new 52 week low
      👍️0
      BooDog BooDog 10 months ago
      Guess I wasn't watching the board here Monk. Have been watching the chart though and have been accumulating around 1.10' last week and added today.

      Cheers
      👍️0
      Monksdream Monksdream 10 months ago
      LXRX new 52 week low
      👍️0
      Monksdream Monksdream 10 months ago
      LXRX new 52 week low
      👍️0
      Monksdream Monksdream 10 months ago
      LXRX new 52 week low
      👍️0
      Monksdream Monksdream 10 months ago
      LXRX new 52 week low
      👍️0
      BooDog BooDog 12 months ago
      LXRX 1.70's. Watching.
      👍️0
      BooDog BooDog 1 year ago
      $LXRX https://finance.yahoo.com/news/lexicon-announces-planned-advancement-lx9211-004500120.html
      Conference call this morning...

      Conference Call and Webcast Information

      Lexicon management will hold a live conference call and webcast Monday, June 26, 2023, at 8:00 am ET / 7:00 am CT. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 7186279. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.
      👍️0
      BooDog BooDog 1 year ago
      👍️0
      BooDog BooDog 1 year ago
      Quite the boost for institutionals.
      https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm
      👍️0
      BooDog BooDog 1 year ago
      Agree. Too easy here. So predictable they'd be doing an offering though. Easy peasy this one is.
      Taking nibbles in the 2.50's. Should have sold more on the highs yesterday.
      👍️0
      TIMGZ TIMGZ 1 year ago
      LXRX MIGHT NOT BE LOOKING BACK AGAN, FDA APPROVED DRUG AND ALL BIG PHARMA EYEING. MY OPINION *******
      ONE PAID $260M FOR BACKING OUT, NOW LOOK AT LXRX
      👍️ 1
      BooDog BooDog 1 year ago
      2.75 support. See how it holds, or not. Interesting sell off.
      👍️0
      glenn1919 glenn1919 1 year ago
      LXRX.........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      BooDog BooDog 1 year ago
      Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.
      👍️0
      glenn1919 glenn1919 1 year ago
      LXRX...........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      BooDog BooDog 1 year ago
      If I se what I think I see, there's a reason shorts are leaving this puppy alone.

      Added back in this morning but when something starts really moving you always say in hindsight that you should have bought more.
      👍️0
      glenn1919 glenn1919 1 year ago
      LXRX.............................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      BooDog BooDog 1 year ago
      High 2.96. Trip and rip potential. That's when the chart show either a tripple bottom or a tripple top and breaks through with some serious momentum.

      See what this puppy does.


      https://www.barchart.com/stocks/quotes/hils/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=LXRX&grid=1&height=210&studyheight=100
      👍️0
      BooDog BooDog 1 year ago
      Passing 2.69.
      👍️0
      BooDog BooDog 1 year ago
      Let's get the move on.
      👍️0
      BooDog BooDog 1 year ago
      PUDUFA coming in a couple months. Looks like they're pretty confident.

      GLTA
      👍️0
      makinezmoney makinezmoney 1 year ago
      $LXRX: Time to load July $3 calls...... now $0.70

      Why ????

      1. Cash on Hand.............. $138.4Milly
      2. Huge Insider buying of shares of $45Milly at $2.50sh
      3. Piper Sandler with $10 Overweight assigned back in August last year
      4. PDUFA coming in MAY
      5. Largest OI is 1k on the July $3 calls


      You know what that means right ???? They gotta a good feeling about that PDUFA
      $LXRX now at $2.44......... last time it spiked ffrom $1.12 to $9.50 from Nov6,2020 to
      Feb1, 2021 ..... 9x bagger !

      Round 2 coming


      GO $LXRX
      👍️0
      BooDog BooDog 2 years ago
      Chart showing some strength. Closes over 2.20 and the bulls will be in the lead for next week imo.

      LXRX daily
      👍️0
      BooDog BooDog 2 years ago
      Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

      THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany:

      “Evaluation of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain: Study Design and Topline Results from the RELIEF-DPN-1 Trial”, describes the positive results achieved in this proof-of-concept study and will be given on Saturday, October 29th at 3:25pm CEST/9:25am ET.


      “Evaluation of LX9211, a Potent, Selective Inhibitor of AAK1, in Preclinical Models of Spasticity”, describes the effect of LX9211 in reducing spasticity in established animal models and will be given on Monday, October 31st at 3:35pm CET/8:35am ET.


      https://finance.yahoo.com/news/lexicon-pharmaceuticals-announces-oral-presentations-125900260.html


      Looks to be waking up.

      LXRX chart
      👍️0

      Your Recent History

      NASDAQ
      LXRX
      Lexicon Pharmaceuticals
      NYSE
      VTMX
      Corporacin Inmobiliaria ...
      USOTC
      MVNT
      Movement Industries (PK)
      USOTC
      FTFY
      Fit After Fifty (CE)
      USOTC
      RLLVF
      Relevium Technologies (CE)
      Delayed Upgrade Clock